Value of combined detection of four tumor markers in diagnosis of patients with lung cancer
-
摘要: 目的 探讨血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)联合神经特异性烯醇化酶(NSE)检测诊断肺癌的价值。 方法 将病理确诊的48例肺癌患者和40例肺部良性病变患者分别为肺癌组和良性病变组,另选取同期门诊常规体检的35名健康人设为健康组。比较3组受试者血清CEA、CA19-9、CA125和NSE水平,分析CEA、CA19-9、CA125和NSE联合检测诊断肺癌的敏感度、特异度和准确度。 结果 肺癌组血清CEA、CA19-9、CA125、NSE水平均显著高于良性病变组和健康组(P<0.05)。TNM Ⅲ~Ⅳ期患者血清CEA、CA19-9、CA125、NSE水平均显著高于TNM Ⅰ~Ⅱ期患者(P<0.05)。血清CEA、CA19-9、CA125、NSE联合检测诊断肺癌的敏感度、准确度均显著高于各指标单项检测(P<0.05), 而联合检测与单项检测的特异度差异无统计学意义(P>0.05)。 结论 血清CEA、CA19-9、CA125、NSE联合检测诊断肺癌的敏感度、准确度均较高,可为临床筛查、诊断提供可靠依据。Abstract: Objective To investigate the value of serum carcinoembryonic antigen(CEA), carbohydrate antigen 19-9(CA19-9), carbohydrate antigen 125(CA125)and neuro-specific enolase(NSE)in diagnosis of patients with lung cancer. Methods Totally 48 patients with diagnosed lung cancer and 40 patients with benign lung disease were selected and designed as lung cancer group and benign lung disease group respectively, and 35 healthy people with routine physical examination in outpatient department at the same time period were selected as healthy group. The serum levels of CEA, CA19-9, CA125 and NSE were compared among the three groups, and the sensitivity, specificity and accuracy of combined detection of CEA, CA19-9, CA125 and NSE in the diagnosis of lung cancer were analyzed. Results The serum levels of CEA, CA19-9, CA125 and NSE in the lung cancer group were significantly higher than those in the benign lung disease group and the healthy group(P<0.05). The levels of CEA, CA19-9, CA125 and NSE in patients in stage Ⅲ to Ⅳ of TNM were significantly higher than those in patients with stage Ⅰ to Ⅱ of TNM(P<0.05). The sensitivity and accuracy of combined detection of serum CEA, CA19-9, CA125 and NSE in the diagnosis of lung cancer were significantly higher than those of single detection(P<0.05), but there was no significant difference in specificity between the combined detection and single detection(P>0.05). Conclusion The sensitivity and accuracy of serum CEA, CA19-9, CA125 and NSE are high in the diagnosis of patients with lung cancer, which can provide reliable references for clinical screening and diagnosis.
-
-
于丽娅, 穆慧娟, 礼彦侠, 等. 辽宁省城市社区2000年肺癌患者分期和治疗方式与5年生存率关联分析[J]. 中华肿瘤防治杂志, 2018, 25(21): 8-13. 赵晶, 李孝吉, 余捍东, 等. 四项肺癌血清肿瘤标志物在肺癌诊断中联合应用效果评估[J]. 基因组学与应用生物学, 2018, 37(2): 661-666. 杨桂学, 吴卓, 张磊, 等. 肺癌患者血清肿瘤标志物与凝血功能变化相关性研究[J]. 现代肿瘤医学, 2018, 26(16): 2519-2523. 李兰曼, 魏玮. 肺癌流行病学和危险因素研究进展[J]. 肿瘤研究与临床, 2018, 30(12): 875-879. 汪育锦, 黄静宇, 胡卫东, 等. 2 403例肺癌临床流行病学分析[J]. 国际肿瘤学杂志, 2019, 46(8): 460-465. 王靖妍, 尹扬, 赵知明. 肺癌血清标志物在健康体检中的价值分析[J]. 癌症进展, 2018, 16(1): 110-112 , 119.
李少雷, 马媛媛, 雄英, 等. 常用血清肿瘤标志物在可手术肺癌患者预后中的价值[J]. 肿瘤防治研究, 2018, 45(1): 30-34. 朱丽, 黎莉. 乳腺癌患者血清糖类抗原153、癌胚抗原、铁蛋白及降钙素水平变化的价值[J]. 中国老年学杂志, 2019, 39(5): 51-53. 许卫娜, 王婷. 患者血清CEA、CA724、CA19-9水平对胰腺癌的评估价值[J]. 实用癌症杂志, 2019, 34(5): 55-57. 方友琴, 方友华, 林开健, 等. 人附睾蛋白4和糖类抗原19-9联合检测在卵巢癌临床诊断与病理分型中的应用价值[J]. 检验医学与临床, 2018, 15(8): 58-61. 徐从斌. 18F-FDG PET/CT联合ProGRP和NSE对小细胞肺癌的临床诊断及分期价值[J]. 临床肺科杂志, 2019, 24(7): 1261-1265. 黄远东, 何朗, 赵晓平, 等. 血清ProGRP、NSE水平与小细胞肺癌化疗疗效及预后的相关性研究[J]. 中国医药导报, 2019, 26(17): 84-87. 龚红娟, 蔡锦洪, 龚菊兰. 血清CYFRA21-1、CEA、NSE、CA19-9、CA125联合检测在肺癌诊断中的价值[J]. 贵州医药, 2019, 43(3): 450-453. 王玲, 申鸿. 癌胚抗原、糖类抗原、CA125、血管生成素、细胞角蛋白19片段及甲胎蛋白检测在肺癌诊断中的临床研究[J]. 陕西医学杂志, 2019, 48(8): 1080-1084.
计量
- 文章访问数: 672
- HTML全文浏览量: 89
- PDF下载量: 16
下载:
苏公网安备 32100302010246号
